No Data
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Xilio Therapeutics Q4 2024 GAAP EPS $(0.20) Beats $(0.21) Estimate, Xilio Anticipates That Its Cash And Cash Equivalents Of $55.3M As Of December 31, 2024, Together With The $52M Upfront Payments Received From AbbVie Is Expected To Provide Cash Runway...
Trump Proposing to Narrow Obamacare Enrollment Period - Report
Amgen Set for Seven Straight Sessions of Gains
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Abbott Laboratories Analyst Ratings
